didate lncRNAs in HCC tissues. qRT-PCR and Western blot analyses were used to detect the expression of FOXD2-AS1. Cell proliferation assays, luciferase assay and RNA immunoprecipitation were performed to examine the mechanism by which FOXD2-AS1 mediates sorafenib resistance in HCC cells. FOXD2-AS1 and TMEM9
were significantly decreased and miR-150-5p was increased in SR-HepG2 and SR-HUH7 cells compared with control parental cells. Overexpression of FOXD2-AS1 increased TMEM9 expression and overcame the resistance of SR-HepG2 and SR-HUH7 cells. Conversely, knockdown of FOXD2-AS1 decreased TMEM9 expression and increased the sensitivity of HepG2 and Huh7 cells to sorafenib. Our data also demonstrated that FOXD2-AS1 functioned as a sponge for miR-150-5p to modulate TMEM9 expression. Taken together, our findings revealed that FOXD2-AS1 is an important regulator of TMEM9 and contributed to sorafenib resistance. Thus, FOXD2-AS1 may serve as a therapeutic target against sorafenib resistance in HCC.
K E Y W O R D S
hepatocellular carcinoma (HCC), long non-coding RNA (lncRNA), pathogenesis, proliferation, resistance, sorafenib high risk of vascular invasion, metastasis, drug resistance and recurrence after surgical resection. 6 Therefore, unravelling the potential molecular mechanism underlying chemotherapeutic resistance in HCC (especially the changes of genetics and epigenetics) is a major focus of research activity.
7
LncRNAs are RNA transcripts >200 nucleotides in length, but lack an obvious open reading frame. 8, 9 Although lncRNA is not translated into protein, lncRNA participates in multiple physiological activities, including chromosome modification, transcription activation and interference, as well as cell growth, differentiation, and apoptosis. 10 Recent studies have demonstrated that several abnormally expressed lncRNAs can mediate drug resistance. For instance, AFAP1-AS1 has been reported to mediate cisplatin resistance in laryngeal cancer cells through the miR-320a/RBP signalling pathway. 11 Overexpression of lncRNA MALAT1 enhances autophagy and chemotherapeutic resistance of gastric cancer (GC) cells through the miR-23B-3P/ATG12 signalling pathway. 12 The lncRNA, H19, up-regulates expression of the multi-drug resistance gene (MDR1), thereby promoting the accumulation of doxorubicin in HCC cells and increasing the acceptable level of toxicity 13 ; however, the role of the lncRNA, FOXD2-AS1, in sorafenib-resistant HCC cells remains elusive. In this study we determined the role of the lncRNA, FOXD2-AS1, which is involved in resistance of HCC to sorafenib and elucidated the underlying mechanism.
| MATERIAL S AND ME THODS

| Patient specimens
In the current study, human HCC specimens were obtained from 60 patients who underwent surgery (34 males and 26 females) be- 
| Microarray analysis
Microarray analysis of gene expression was performed according to the manufacturer's instructions (Agilent Technologies Co., Ltd., Santa Clara, CA). Briefly, 50 ng of purified mRNA was amplified and transcribed into double-stranded complementary DNA (cDNA). As previously described, 8 the cDNA was labelled and hybridized to human lncRNA Array v3.0 (Arraystar, Inc, Rockville, MD), according to the manufacturer's instructions. The original data were standardized and corrected using GenePix Pro 4.0 software. The comparison between HepG2 and SR-HepG2 samples was analysed by a t test. LncRNAs with a P < 0.05 were selected and cluster analysis was carried out using the hierarchical method, average linkage and Euclidean distance metrics.
| RNA isolation and qRT-PCR
According to the manufacturer's instructions, total RNA was extracted 
| Plasmid construction
The scramble shRNA sequence or shRNA targeting FOXD2- 
| Dual-luciferase reporter gene assay
Dual-luciferase reporter gene assay was carried out, as described below. Cells (3 × 10 5 ) were cultured in 24-well plates and cotransfected with 2 ng pRL-TK (Promega) 10 ng of luciferase plasmids, and 100 ng of miR-150-5p mimic or negative control. The luciferase activity in the cells was detected 48 hours after transfection using a luciferase assay kit (Promega) and standardized with Ranilla luciferase activity. The experiments were repeated three times.
| Cell transfection
The chemically synthesized TMEM9-specific siRNA (5′-GAATGACACAGCAATGAA-3′) miR-150-5p mimics, miR-150-5p
inhibitors and miRNA controls (miR-NC) were purchased from GENECHEM (Shanghai, China). Using Lipofectamine 3000
(Invitrogen), TMEM9-FLAG plasmid, TMEM9 siRNA, scrambled siRNA, miRNA mimics, miRNA inhibitors and miRNA controls were transfected into the cells according to the manufacturer's instructions.
| Statistical analysis
All statistical analyses were performed using GraphPad Prism Figure 1E ). Moreover, sorafenib down-regulated the level of FOXD2-AS1 expression in HepG2 and HUH7 cells in a dose-dependent manner ( Figure 1C ). Taken together, these results suggest that FOXD2-AS1 plays a key role in sorafenib resistance in HCC.
| FOXD2-AS1 binds to miR-150-5p
To determine whether FOXD2-AS1 binds miRNAs, the potential binding force of miRNAs and FOXD2-AS1 was predicted using starBase v.2.0 software (Figure 2A ). Among the potential miRNAs, the
F I G U R E 3 FOXD2-AS1 regulates TMEM9 expression. (A) TMEM9 expression in HepG2, HUH7, RS-HepG2 and RS-HUH7 cells. (B) TMEM9 in HepG2 and HUH7 cells treated with sorafenib. (C) FOXD2-AS1 expression in SR-HepG2 and SR-HUH7 cells 48 h after transfection with lentivirus expressing FOXD2-AS1 or empty vector. (D,E) TMEM9 expression in SR-HepG2 and SR-HUH7 cells overexpressing FOXD2-AS1. (F) FOXD2-AS1 expression in HepG2 and Huh7 cells 48 h after shRNA1 or 2. (G-H) The expressions of TMEM9 in SR-HepG2 and SR-HUH7 cells overexpressing FOXD2-AS1. (I) FOXD2-AS1 was mainly distributed in the cell cytoplasm. (J)
Pearson correlation analysis was conducted to evaluate the correlation between fox FOXD2-AS1 and TMEM9 mRNA in hepatocellular carcinoma tissue samples. *P < 0.05 expression of miR-150-5p was significantly up-regulated in sorafenibresistant HCC cells ( Figure 2B ). In HCC tissue specimens, FOXD2-AS1
was negatively correlated with miR-150-5p expression ( Figure 2C ).
Moreover, endogenous FOXD2-AS1 precipitated by AGO2 tended to be enriched in cells overexpressing miR-150-5p, but not miR-372
( Figure 2D) . Additionally, the dual-luciferase assay showed that cotransfection of miR-150-5p mimics with FOXD2-AS1 WT (pmir-GLEWT-FOXD2-AS1), rather than the pmirGLE-mut-FOXD2-AS1 mutant, significantly reduced luciferase activity ( Figure 2E ). Together, these results suggest that FOXD2-AS1 binds to miR-150-5p.
| FOXD2-AS1 enhances TMEM9 expression
TMEM9 is an important regulator in the progression of HCC. Moreover, the expression of FOXD2-AS1 in HCC tissue samples was positively correlated with TMEM9 expression (R 2 = 0.4207, P < 0.05, Figure 3J ). Collectively, these results suggest that TMEM9 is a target of FOXD2-AS1 in HCC.
| FOXD2-AS1 regulates TMEM9 expression by acting as aceRNA of miR-150-5p
The luciferase reporter assay showed that transfection with miR-150-5p mimics significantly reduced the activity of TMEM9 3'UTR, but had no apparent effect on TMEM9 3'UTR mut ( Figure 4A,B) .
Overexpression of FOXD2-AS1, but not FOXD2-AS1-mut, remarkably increased the luciferase activity of TMRM9 3′UTR, whereas cotransfection with miR-150-5p inhibited this effect ( Figure 4C ). 
| FOXD2-AS1 reverses sorafenib resistance in HCC cells by regulating TMEM9 expression
We then determined whether FOXD2-AS1 regulates sorafenib resistance via the miR-150-5p/TMEM9 axis. Compared with control cells, overexpression of FOXD2-AS1 significantly increased the sensitivity of SR-HepG2 and SR-Huh7 cells to sorafenib resistance, whereas knockdown of TMEM9 or overexpression of miR-150-5p reversed this effect ( Figure 5A,B) . Similarly, FOXD2-AS1 increased the apoptotic rates of SR-HepG2 and SR-Huh7 cells and TMEM9
depletion or miR-150-5p overexpression restrained the apoptosis induced by FOXD2-AS1 ( Figure 5C ). Conversely, knockdown of FOXD2-AS1 increased sorafenib resistance and reduced apoptosis in SR-HepG2 and SR-Huh7 cells, whereas overexpression of TMEM9
or treatment with miR-150-5p inhibitor reversed the effects mediated by FOXD2-AS1 depletion ( Figure 5D ,E). Together, these results suggest that FOXD2-AS1 contributes to sorafenib resistance by targeting the miR-150-5p-5p/TMEM9 axis.
| FOXD2-AS1 inhibits the NRf2 signalling pathway by regulating TMEM9 expression
Western blot analysis demonstrated FOXD2-AS1 overexpres- Moreover, in SR-HepG2 and SR-HUH7 cells, the ARE-driven luciferase activity was decreased by FOXD2-AS1 in a dose-dependent manner, which was partially reversed by overexpression of miR-150-5p ( Figure 6C ). In HepG2 and HUH7 cells with the silencing of FOXD2-AS1, the ARE-driven luciferase activity was increased in a dose-dependent pattern, and this effect was partially blocked by miR-150-5p inhibitor ( Figure 6D ). In the present study, a group of lncRNAs differentially expressed in sorafenib-resistant HCC cells were validated.
| D ISCUSS I ON
In this study, we confirmed that down-regulation of FOXD2-AS1
and TMEM9 expression was positively correlated with the increase in cells, and these effects were partially blocked by miR-150-5p mimics.
In contrast, inHepG2 and HUH7 cells with silencing of FOXD2-AS1, ARE-driven luciferase activity was increased in a dose-dependent manner, which was partially blocked by miR-150-5p inhibitor. These results indicate that FOXD2-AS1 regulates the Nrf2 signalling pathway via the miR-150-5p/TMEM9 pathway.
| CON CLUS ION
Taken together, FOXD2-AS1 is a novel key regulator of TMEM9 and mediates sorafenib resistance in HCC cells. FOXD2-AS1 competes with the 3'UTR of TMEM9 for binding with miR-150-5p, which promotes the expression of TMEM9, inhibits the Nrf2-ARE signalling pathway, and reverses sorafenib resistance in HCC cells. The finding that the FOXD2-AS1/miR-150-5p/TMEM9 signalling pathway is involved in sorafenib resistance may provide novel strategies to overcome sorafenib resistance in HCC.
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